Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T C Chan

Showing results (341-350 of 407) with videos related to

Pageof 41
Sort By:
The Oncologist|September 13, 2021
Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective TrialsWinnie Yeo, Frankie K F Mo, Christopher C H Yip, et al.
Clinical Chemistry|March 20, 2020
Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant ProfilesW K Jacky Lam, Lu Ji, O Y Olivia Tse, et al.
AJNR. American Journal of Neuroradiology|December 30, 2017
MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign HyperplasiaA D King, L Y S Wong, B K H Law, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancerGraham S Taylor, Hui Jia, Kevin Harrington, et al.
Cancer Letters|September 18, 2013
Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer modelsBrigette B Y Ma, Vivian W Y Lui, Connie W C Hui, et al.
JAMA Network Open|June 2, 2023
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled TrialNancy Y Lee, Jonathan Harris, John Kim, et al.
JAMA Network Open|December 21, 2022
Association of Maternal and Paternal Astigmatism With Child Astigmatism in the Hong Kong Children Eye StudyKa Wai Kam, Arnold S H Chee, Yuzhou Zhang, et al.
European Radiology|March 24, 2019
Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRIQi-Yong Ai, Ann D King, Janet S M Chan, et al.
Cancer Medicine|February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Oncogene|July 25, 2006
The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formationT J Seng, J S W Low, H Li, et al.
Pageof 41

Showing results (341-350 of 407) with videos related to

Sort By:
Pageof 41
The Oncologist|September 13, 2021
Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective TrialsWinnie Yeo, Frankie K F Mo, Christopher C H Yip, et al.
Clinical Chemistry|March 20, 2020
Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant ProfilesW K Jacky Lam, Lu Ji, O Y Olivia Tse, et al.
AJNR. American Journal of Neuroradiology|December 30, 2017
MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign HyperplasiaA D King, L Y S Wong, B K H Law, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancerGraham S Taylor, Hui Jia, Kevin Harrington, et al.
Cancer Letters|September 18, 2013
Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer modelsBrigette B Y Ma, Vivian W Y Lui, Connie W C Hui, et al.
JAMA Network Open|June 2, 2023
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled TrialNancy Y Lee, Jonathan Harris, John Kim, et al.
JAMA Network Open|December 21, 2022
Association of Maternal and Paternal Astigmatism With Child Astigmatism in the Hong Kong Children Eye StudyKa Wai Kam, Arnold S H Chee, Yuzhou Zhang, et al.
European Radiology|March 24, 2019
Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRIQi-Yong Ai, Ann D King, Janet S M Chan, et al.
Cancer Medicine|February 3, 2026
Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122Anthony T C Chan, Victor Ho Fun Lee, Ruey-Long Hong, et al.
Oncogene|July 25, 2006
The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formationT J Seng, J S W Low, H Li, et al.
Pageof 41